Tara Lin, MD, University of Kansas Medical Center, Kansas City, Kansas, discusses how she approaches choosing induction therapy for patients with treatment-related acute myeloid leukemia, emphasizing that fitness…
In the video, Shelley, a 70-year-old diagnosed with acute myeloid leukemia after her chronic myelomonocytic leukemia progressed, shares her cancer journey and how participating in a clinical trial…
In a study of 16,331 patients in the California Cancer Registry, 5.7% developed a second primary malignancy more than 1 year after diagnosis. The 10-year cumulative incidence of…
Jolan Walter, MD, PhD, division chief of the University of South Florida (USF) and Johns Hopkins All Children’s Pediatric Allergy & Immunology Programs, discusses the importance of long-term…
In this HemaSphere review, researchers share details about recent progress related to gene therapy technologies and procedures for primary immunodeficiency. Transduction of hematopoietic stem cells using lentiviral vectors…
In a study designed to investigate the biological relevance of PARP1 in multiple myeloma (MM), data revealed a significant correlation between increased PARP1 mRNA expression and poor prognosis…
In a study designed to analyze and improve the diagnostic sensitivity and specificity of the immunodeficiency disease-related scoring system in adult patients referred to immunology with clinical suspicion…
Corey Cutler, MD, MPH, medical director of the Adult Stem Cell Transplantation Center at Dana-Farber Cancer Institute, discusses Blood and Marrow Clinical Trials Network Study 1102, comparing patients…
Phase 3 ASCERTAIN Trial Shows Promising Results with Oral Decitabine and Cedazuridine Combination for the Treatment of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia
Naval Daver, MD, University of Texas MD Anderson Cancer Center, shares recent work on combination magrolimab, a CD47-targeting monoclonal antibody, and the hypomethylating agent azacitidine. The azacitidine and…
Sergio Rutella, MD, PhD, FRCPath, hematologist and professor of cancer immunotherapy at the John van Geest Cancer Research Centre, reports new findings from his work on acute myeloid…
Thomas Prebet, MD, PhD, Yale School of Medicine, previews recent advancements and treatment options for acute myeloid leukemia (AML) patients with TP53, IDH, and FLT3 mutations. Dr. Prebet…
